Everest Medicines Ltd. has acquired rights to develop and commercialize Nefecon (budesonide) for the treatment of primary IgA nephropathy in South Korea from Calliditas Therapeutics AB.
Hansoh Pharmaceutical Group Co. Ltd. has won a green light for inebilizumab, approved by China’s NMPA for the treatment of adults with neuromyelitis optica spectrum disorders (NMOSD) who are anti-aquaporin-4 immunoglobulin G (AQP4-IgG) seropositive. The decision marked Hansoh’s first biologic approval.
The U.S. Securities and Exchange Commission (SEC) recently issued a provisional list of five U.S.-listed Chinese companies that reportedly failed to submit necessary accounting reports required under Holding Foreign Companies Accountable Act. The list included three biopharmas: Beigene Ltd., Hutchmed Ltd., and Zai Lab Ltd.
Chinese state-owned enterprise China Meheco Group Co. Ltd. has signed a deal with Pfizer Inc. to be its mainland China partner for the commercialization of the COVID-19 pill Paxlovid (nirmatrelvir and ritonavir), which won conditional approval from China’s NMPA earlier this year.
Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications: Biontech, Coherus, Eli Lilly, Immvira, Incyte, Inovio, Junshi, Kintor, Nicox, Novavax, Ocumension, Pfizer, SAB.
Biopharma happenings in Asia-Pacific, such as deals and partnerships, grants, preclinical data and other news in brief: Affinivax, Akeso, Aquestive, Astellas, Blue Willow, EA, Genome, Haisco, Incannex Healthcare, JCR, Medigen Vaccine, Merck, Pathalys, Shenzhen Chipscreen, Sorrento, Sumitomo Dainippon.
Hutchmed Ltd. has received a $15 million milestone payment from Astrazeneca plc for initiating a phase III trial testing the Hutchmed c-Met inhibitor Orpathys (savolitinib) in combination with Astrazeneca’s Tagrisso (osimertinib) in EGFR-mutated non-small-cell lung cancer.
RSS
